CE Mark for PASCAL Precision transcatheter valve repair system for the treatment of mitral and tricuspid regurgitation
Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR)
The PASCAL Precision system is utilized in the treatment of patients with mitral or tricuspid regurgitation, through a single delivery system. The new system is designed to enable precise navigation and implant delivery. The PASCAL Precision system includes PASCAL and PASCAL Ace implants, which feature independent grasping, atraumatic clasp and closure, and implant versatility including the ability to elongate and navigate complex anatomy.
"The PASCAL Precision system provides significant advancements in operator experience with implant delivery," said Prof Jörg Hausleiter, Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilians University in Munich, Germany. "Having successfully treated my first patient with the PASCAL Precision system, I found it easy to operate and the improved catheter response and stability gave me greater control to place the implant exactly where I needed to."
Related news and insights
Bausch Health Companies Inc. and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. announce that Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older
Takeda announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for the potential expanded use of Takhzyro (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age
Eiger BioPharmaceuticals announced that, following feedback from the FDA, the company will not submit an emergency use authorization (EUA) application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19